Clean copy of pending claims as amended in this response:

1. A stable liquid pharmaceutical botulinum toxin formulation, comprising

a pharmaceutically acceptable buffer capable of providing a buffered pH range between about pH 5 and pH 6, and

isolated botulinum toxin;

wherein said formulation is stable as a liquid for at least one year at a temperature between about 0 and 10 degrees centigrade.

A1

2. The formulation of claim 1, wherein said temperature is about 5±3 degrees centigrade.

3. The formulation of claim 1, wherein said temperature is about 4±2 degrees centigrade.

4. The formulation of claim 1, wherein said buffered pH range is about pH 5.6±0.2.

5. The formulation of claim 1, wherein said toxin formulation is stable in liquid form for at least two years.

6. The formulation of claim 1, wherein said buffer has a pK in the range of pH 4.5-6.5.

7. The formulation of claim 6, wherein said buffer is selected from the group consisting of phosphate buffer, phosphate-citrate buffer, and succinate buffer.

A2

8. The formulation of claim 1, wherein said botulinum toxin is of a botulinum toxin type selected from the group consisting of Types A, B, C_1, C_2, D, E, F and G.

9. The formulation of claim 8, wherein said botulinum toxin is botulinum toxin Type B present at a concentration in the range of about 100-20,000 U/ml.

10. The formulation of claim 9, wherein said botulinum toxin Type B is present in a high molecular weight complex of about 700 kilodaltons (kD).

11. The formulation of claim 9, wherein said botulinum toxin Type B is present at a concentration between about 1000-5000 U/ml.

12. The formulation of claim 8, wherein said botulinum toxin is botulinum toxin Type A, present at a concentration in the range of about 20-2000 U/ml.

13. The formulation of claim 12, wherein said botulinum toxin Type A is present at a concentration in the range of about 100-1000 U/ml.

14. The formulation of claim 1, which further includes an excipient protein.

15. The formulation of claim 14, wherein said excipient protein is selected from the group consisting of serum albumin, recombinant human serum albumin, and gelatin.

16. A stable liquid pharmaceutical botulinum toxin formulation, comprising

a pharmaceutically acceptable liquid buffer capable of providing a buffered pH range between about pH 5 and pH 6, and

isolated botulinum toxin;

wherein said toxin formulation is stable as a liquid for at least about 6 months at a temperature between about 10 and 30 degrees centigrade.

17. The formulation of claim 16, wherein said temperature is about 25°C.

18. The formulation of claim 16, wherein said buffered pH range is about pH 5.6 ± 0.2.

19. The formulation of claim 16, wherein said buffer has a pK in the range of pH 4.5-6.5.

20. The formulation of claim 19, wherein said buffer is selected from the group consisting of phosphate buffer, phosphate-citrate buffer, and succinate buffer.

A3

21. The formulation of claim 16, wherein said botulinum toxin is of a botulinum toxin type selected from the group consisting of Types A, B, C_1, C_2, D, E, F and G.

22. The formulation of claim 21, wherein said botulinum toxin is botulinum toxin Type B present at a concentration of about 100-20,000 U/ml.

23. The formulation of claim 22, wherein said botulinum toxin Type B is present in a high molecular weight complex of about 700 kD.

24. The formulation of claim 22, wherein said botulinum toxin Type B is present at a concentration in the range of about 1000-5000 U/ml.

25. The formulation of claim 21, wherein said botulinum toxin is botulinum toxin Type A, present at a concentration in the range of about 20-2000 U/ml.

26. The formulation of claim 25, wherein said botulinum toxin is botulinum toxin Type A, present at a concentration in the range of about 100-1000 U/ml.

27. The formulation of claim 16, which further includes an excipient protein.

28. The formulation of claim 25, wherein said excipient protein is selected from the group consisting of serum albumin, human serum albumin, and gelatin.